个体化治疗时代的老年晚期非小细胞肺癌治疗ppt课件.pptVIP

Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced NSCLC 2010 ASCO Abstract No：2 2010 ASCO Abstract No：2 Response Rate at 6 Weeks (ITT) *Main causes : deaths (20 in arm A and 23 in arm B), reduced general condition (respectively 7 and 4), toxicity 0 and 4 cases respectively and withdrawal of consent (6 cases) 2010 ASCO Abstract No：2 PFS (ITT) 6.2 2010 ASCO Abstract No：2 Overall Survival (ITT) 2010 ASCO Abstract No：2 Exploratory Sub-group Analysis Favors Doublet Favors Single Agent